Recent Updates
Recently added Catalysts
NVAX

Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference

Key Takeaway: GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference. Presentation details are as follows: Date: Thursday, January 12, 2017 Time: 9:30 am U.S. Pacific

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
SARS-CoV-2 rS/Matrix-M1 Adjuvant
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Thursday, January 12, 2017
Time: 9:30 am U.S. Pacific Time
Location: California East room, Westin St. Francis Hotel, San Francisco
Live webcast: novavax.com, “Investors”/ “Events”
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Last updated: Jan 5, 2017